FAQ

FAQ published on September 11, 2017
Join Dr. John Sweetenham as he discusses the risk factors that may predict ASCT outcomes including, primary refractory disease and extranodal disease.
FAQ published on August 7, 2017
Join Dr. Younes as he discusses how genome sequencing data should be applied to clinical practice of HL.
FAQ published on July 24, 2017
Dr. Stephen Ansell explains the mechanism of action and the role of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma.
FAQ published on June 19, 2017
Dr. Stephen Ansell explains the mechanism of action and the role of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma.
FAQ published on June 7, 2017
Join Dr. Ansell as he discusses the new PD-1 blocking antibodies that are showing response in HL patients post-transplant.
FAQ published on December 7, 2016
Join Dr. Paul Bröckelmann as he discusses where nivolumab fits in treating patients with classical Hodgkin lymphoma.
FAQ published on November 2, 2016
Join Dr. Paul Bröckelmann as he discusses treatment options for HL patients who are at risk for relapse or disease progression after transplant.
FAQ published on October 5, 2016
Join Dr. Paul Bröckelmann as he discusses how to identity HL patients who are at risk for relapse or disease progression after transplant.
FAQ published on September 6, 2016
Join Dr. Robert Chen as he discusses new and emerging treatments in HL that are most likely to have the greatest impact on improving outcomes for relapsed or refractory disease.
FAQ published on August 4, 2016
Join Dr. Andrew Evens as he explains the relative roles of immunohistochemical studies versus flow cytometry results in the accurate diagnosis and assessment of patients with Hodgkin lymphoma.
Page 1 of 6
Results 1 - 10 of 54

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved